%0 Journal Article
%A Evans, Rhiannon 
%A Lavín Plaza, Begoña
%A Phinikaridou, Alkystis
%A Chooi, Kok Yean
%A Mohri, Zahra
%A Wong, Eunice
%A Boyle, Joseph 
%A Krams, Rob
%A Botnar, René
%A Long, Nicholas 
%T Targeted molecular iron oxide contrast agents for imaging atherosclerotic plaque
%D 2020
%@ 2206-7418
%U https://hdl.handle.net/20.500.14352/97000
%X Cardiovascular disease remains a leading cause of death worldwide, with vulnerable plaque rupture the underlying cause of many heart attacks and strokes. Much research is focused on identifying an imaging biomarker to differentiate stable and vulnerable plaque. Magnetic Resonance Imaging (MRI) is a non-ionising and non-invasive imaging modality with excellent soft tissue contrast. However, MRI has relatively low sensitivity (micromolar) for contrast agent detection compared to nuclear imaging techniques. There is also an increasing emphasis on developing MRI probes that are not based on gadolinium chelates because of increasing concerns over associated systemic toxicity and deposits1. To address the sensitivity and safety concerns of gadolinium this project focused on the development of a high relaxivity probe based on superparamagnetic iron oxide nanoparticles for the imaging of atherosclerotic plaque with MRI. With development, this may facilitate differentiating stable and vulnerable plaque in vivo.
%~